Charcot-Marie-Tooth type 2A in vivo models: Current updates.

Area of Science:

• Neuroscience
• Genetics
• Cell Biology

Background:

• Charcot-Marie-Tooth type 2A (CMT2A) is an inherited sensorimotor neuropathy caused by mutations in the Mitofusin 2 (MFN2) gene.
• MFN2 mutations disrupt mitochondrial dynamics, mitophagy, and axonal transport, leading to significant patient disability.
• Currently, no definitive treatment exists for CMT2A.

Purpose of the Study:

• To critically review and update the literature on mammalian experimental models for CMT2A.
• To highlight the characteristics and translational utility of these models in developing therapeutic strategies.
• To discuss current limitations and future directions for CMT2A model development.

Main Methods:

• Literature review of experimental models for Charcot-Marie-Tooth type 2A.
• Analysis of phenotypic, histopathological, and molecular characteristics of mammalian models.
• Evaluation of the translational application of these models in drug discovery and therapeutic development.

Main Results:

• Murine models are the most versatile and widely used for CMT2A research.
• Various models exhibit distinct phenotypic, histopathological, and molecular features relevant to CMT2A.
• These models are instrumental in preclinical studies for evaluating potential CMT2A therapies.

Conclusions:

• Reliable experimental models, particularly mammalian ones, are essential for dissecting CMT2A pathogenesis.
• Continued refinement of these models is necessary to accelerate the development of effective treatments for CMT2A patients.
• Understanding model limitations is key to advancing translational research from bench to bedside.